15-year follow-up on radiotherapy treatment after surgery for ductal carcinoma in situ

Need for updated breast cancer guidelines and screening programs

FLIMS workshop and management of triple negative breast cancer

Debate on breast cancer screening contributing to drop in mortality

Triple negative advanced breast cancer treatment with PARP inhibitors

Highlights from EBCC 8 and looking to EBCC 9

ECCO and cancer care in Europe

Managing the toxicity of aromatase inhibitors

New technology for identifying and removing micro metastases in breast cancer patients

Managing HER2 overexpression in breast cancer

Debate on the success of breast cancer screening programmes

Analysis of thirty years of clinical trial data